Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A

International Journal of Medical Sciences

Volumn 3, Issue 4, 2006, Pages 135-140

  Ishida, Yoshiko ^a   Goto, Yasuyuki ^a   Kondo, Takaaki ^a   Kurata, Mio ^a   Nishio, Kazuko ^a   Kawai, Sayo ^a   Osafune, Tomo ^a   Naito, Mariko ^a   Hamajima, Nobuyuki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP2C19; Eradication; Helicobacter pylori; IL 1B; TNF A

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; INTERLEUKIN 1BETA; LANSOPRAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

EID: 33749514137     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.3.135     Document Type: Article

References (33)

1. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35: 19-22.
2. IARC. Infection with Helicobacter pylori. In: IARC monographs on the evaluation of the carcinogenic risks to humans. Lyon, France: International Agency for Research on Cancer. 1994: 177-241.
3. Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005; 23: 8018-24.
4. Kohda K, Kuga T, Kogowa K, et al. Effective of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol. 2002; 118: 584-8.
5. Suzuki T, Matsushima M, Masui A, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura - a randomized controlled trial. Am J Gastroenterol. 2002; 100: 1271-3.
6. Fukuda S, Shimoyama T, Umegaki N, et al. Effect of Helicobacter pylori eradication in the treatment of Japanese patients with chronic idiopathic urticaria. J Gastroenterol. 2004; 29: 827-30.
7. Franceschi F, Leo D, Fini L, et al. Helicobacter pylori infection and ischaemic heart disease: an overview of the general literature. Dig Liver Dis. 2005; 37: 301-8.
8. Figura N, Piomboni P, Ponzetto A, et al. Helicobacter pylori infection and infertility. Eur J Gastroenterol Hepatol. 2002; 14: 663-9.
9. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997; 6: 639-42.
10. Malfertheiner P, Sipponen P, Naumann M, et al. H. pylori-Gastric Cancer Task Force. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol. 2005; 100: 2100-115.
11. Ford A.C, Forman D, Bailey A.G, et al. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology. 2005; 129: 1910-7.
12. Sone Y, Kumada T, Kiriyama S, et al. Helicobacter pylori eradication reduces medical care costs: a community-based study. Helicobacter Res. 2002; 6: 299-304.
13. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter. 2001; 6: 254-61.
14. Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005; 3: 564-73.
15. Take S, Mizuno M, Ishiki K, et al. Interleukin-1 β genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol. 2003; 98: 2403-8.
16. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2003; 17: 259-65.
17. Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistence and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol. 2003; 15: 27-33.
18. Furuta T, Shirai N, Xiao F, et al. Polymorphism of interleukin-1B affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol. 2004; 2: 22-30.
19. Hamajima N, Matsuo K, Saito T, et al. Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection. Jpn J Cancer Res. 2001; 92: 383-9.
20. Beales I.L, Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut. 1998; 42: 227-34.
21. Hamajima N, Shibata A, Katsuda N, et al. Subjects with TNF-A-857TT and -1031TT genotypes showed the highest Helicobacter pylori seropositive rate compared with those with other genotypes. Gastric Cancer. 2003; 6: 230-6.
22. Hamajima N, Saito T, Matsuo K, et al. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res. 2000; 91: 865-8.
23. Atsuta Y, Kawase H, Hamajima N, et al. Use of duplex PCR-CTPP methods for CYP2E1 RsaI/IL-2 T-330G and IL-1B C-31T/TNF-A T-1031C polymorphisms. Mol Diagn. 2005; 9: 89-94.
24. Sugimoto M, Furuta T, Shirai N, et al.. Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Aliment Pharmacol Ther. 2005; 22: 1033-40.
25. Sapone A, Vaira D, Trespidi S, et al. The clinical role of cytochrome P450 genotypes in Helicobacter pylori management. Am J Gastroenterol. 2003; 98: 1010-15.
26. Timm R, Kaiser R, Lotsch J, et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J. 2005; 5: 365-73.
27. Hamajima N, Ito H, Matsuo K, et al. Helicobacter pylori seropositivity, the interleukin 1B polymorphism, and smoking among first-visit outpatients. Asian Pac J Cancer Prev. 2002; 3: 23-8.
28. Zambon CF, Basso D, Navaglia F, et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine. 2005; 29: 141-52.
29. Skoog T, van't Hooft FM, Kallin B, et al. A common functional polymorphism (C - >A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet. 1999; 8: 1443-9.
30. Kamada T, Haruma K, Komoto K, et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin and clarithromycin. Helicobacter. 1999; 4: 204-10.
31. Perri F, Villani M.R, Festa V, et al. Predictors of failure of Helicobacter pylori eradication with the standard "Maastricht triple therapy. Aliment Pharmacol Ther. 2001; 15: 1009-23.
32. Matsuo K, Hamajima N, Ikehara Y, et al. Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin. Epidemiol Infect. 2003; 130: 227-33.
33. Saitoh T, Fukushima Y, Otsuka H, et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther. 2002; 16: 1811-17.